By Lina carolina 
A protein, initially recognized nearly four decades ago for its vital role in stimulating red blood cell production, has been unveiled as a critical, yet previously unrecognized, player in dampening the immune system’s response to cancer. This groundbreaking discovery, detailed in a recent publication in the prestigious journal Science, centers on erythropoietin (EPO) and its surprising capacity to act as a key suppressor of anti-tumor immunity. Researchers have demonstrated that by blocking EPO’s activity, they can transform notoriously "cold," or immune-resistant, liver tumors in mice into "hot" tumors, teeming with cancer-fighting immune cells. This transformation, when coupled with existing immunotherapies, has led to the complete regression of established liver tumors in a significant majority of the animal models, with treated animals surviving for the duration of the experiment, a stark contrast to control groups that succumbed within weeks.
This fundamental shift in understanding how the immune system is regulated in the context of cancer has ignited considerable excitement within the scientific community. Dr. Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine at Stanford University, and the senior author of the study, expressed profound optimism. "This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," Dr. Engleman stated. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials." The lead author of the study is Dr. David Kung-Chun Chiu, PhD, a basic life research scientist who spearheaded the intricate experimental design.
Unraveling the Dual Nature of Erythropoietin
The journey to understanding EPO’s immunosuppressive role began with observations that predated the current study by over a decade. Historically, EPO was administered to cancer patients suffering from anemia to stimulate red blood cell production. However, researchers noted a concerning correlation: this treatment appeared to accelerate tumor growth. This link was so pronounced that by 2007, the U.S. Food and Drug Administration (FDA) mandated a black box warning on EPO-based drugs, cautioning against their use in cancer patients due to increased risks. Further research solidified this connection, revealing a clear correlation between elevated levels of naturally occurring EPO and its receptor within tumors and poorer patient prognoses.
"Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman explained. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This established identity as a growth factor for red blood cells, vital for oxygen transport, had seemingly overshadowed any potential immune-modulatory functions.
From Anemia Treatment to Immune Evasion: A Timeline of Discovery
The path to this revelation was a meticulous, multi-year endeavor, characterized by rigorous experimentation and a willingness to challenge long-held assumptions.
- 1980s: Erythropoietin (EPO) is identified and characterized for its primary function: stimulating the production of red blood cells in response to low oxygen levels.
- Early 2000s: Clinical observations emerge linking the use of EPO for anemia in cancer patients to accelerated tumor growth.
- 2007: The U.S. Food and Drug Administration (FDA) issues a black box warning for EPO-based drugs, advising against their use in cancer patients due to increased tumor progression risks.
- Mid-2010s: Advances in cancer immunotherapy, particularly checkpoint inhibitors like anti-PD-1 therapies, show remarkable success in treating certain cancers but highlight a significant challenge: many tumors remain resistant. Researchers begin investigating the mechanisms behind this resistance.
- Late 2010s – Early 2020s: Dr. David Kung-Chun Chiu and his team at Stanford University develop sophisticated mouse models of liver cancer, incorporating specific mutations found in human liver tumors. These models are crucial for dissecting the complex tumor microenvironment and its interaction with the immune system.
- Present: The research published in Science reveals EPO’s pivotal role in rendering tumors "cold" and resistant to immune attack. The study demonstrates that blocking EPO signaling, in conjunction with immunotherapy, can convert cold tumors to hot and lead to significant tumor regression in mice.
Sophisticated Mouse Models Pave the Way for Breakthroughs
At the heart of this discovery lies the innovative work of Dr. Chiu, who employed cutting-edge genome editing techniques to engineer several distinct mouse models of liver cancer. These models were designed to meticulously recapitulate the specific genetic mutations, histological characteristics, and responses to established therapies observed in various subtypes of human liver cancers. Tumor formation in these models was induced either by direct injection of DNA encoding proteins known to be associated with liver cancer development into the animals’ tail veins or by implanting pre-existing liver cancer cells directly into their livers. This precise control over the tumor microenvironment allowed researchers to investigate the impact of specific genetic alterations on tumor behavior and immune system interaction.
The researchers’ initial focus was on the efficacy of a common immunotherapy targeting the PD-1 molecule, found on T cells, a critical component of the immune system. Binding of PD-1 by cancer cells normally serves as a "brake," suppressing T cell activity and allowing tumors to evade immune detection. Therapies designed to block this interaction, such as the widely used anti-PD-1 drugs, have revolutionized treatment for cancers like melanoma, Hodgkin’s lymphoma, and certain lung cancers. However, a significant limitation of these therapies is their lack of effectiveness against a broad spectrum of "cold" tumors, including most liver, pancreatic, colon, breast, and prostate cancers.
Identifying the "Cold" Tumor Signature and EPO’s Role
In their experimental mouse models, the researchers observed a phenomenon mirroring human liver cancers: certain combinations of mutations led to the development of liver tumors that were largely ignored by the immune system. These "cold" tumors were characterized by a scarcity of cancer-fighting T cells, rendering them immune-privileged and unresponsive to anti-PD-1 treatment. In stark contrast, other tumor subtypes, driven by different mutations, developed into "hot" or "inflamed" tumors, densely populated with T cells and highly sensitive to anti-PD-1 therapy, which effectively unleashed the T cells to attack the cancer.
The crucial, and unexpected, finding emerged when the researchers analyzed EPO levels in these distinct tumor types. They discovered that the cold tumors exhibited significantly elevated levels of EPO compared to their hot counterparts. This increase is strongly suspected to be a consequence of the oxygen-poor microenvironment, or hypoxia, commonly found in cold tumors. Hypoxia triggers cancer cells to produce specific proteins that, in turn, stimulate EPO production. The rationale behind this cellular response is to generate more red blood cells, thereby increasing oxygen supply to the oxygen-deprived tumor.
"Hypoxia in tumors has been studied for decades," Dr. Engleman remarked. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This observation challenged the established dogma and opened a new avenue of investigation into EPO’s role beyond its hematopoietic function.
Experimental Validation: Manipulating EPO Levels and Tumor Response
To confirm their hypothesis, the research team delved into existing databases, corroborating that elevated EPO levels are indeed associated with poorer survival rates in patients with various cancers, including liver, kidney, breast, colon, and skin cancers. The pivotal experiments involved genetically modifying tumor cells to either reduce or eliminate their ability to produce EPO. The results were striking. Tumors that had initially developed as "cold" and immune-resistant transformed into "hot" tumors when their EPO production was suppressed. Conversely, "hot" tumors that had previously been effectively cleared by the immune system began to thrive when engineered to produce elevated levels of EPO.
Further detailed investigations elucidated the precise mechanism by which EPO exerts its immunosuppressive effects. In cold tumors, the tumor cells secrete EPO, which then binds to receptors on the surface of immune cells known as macrophages. Upon binding EPO, these macrophages transition from potentially anti-tumor roles to adopting a profoundly immunosuppressive posture. They actively deter cancer-killing T cells from infiltrating the tumor microenvironment and significantly dampen the activity of those T cells that do manage to reach the tumor. This intricate crosstalk between tumor cells and macrophages, mediated by EPO, proved to be a cornerstone of immune evasion.
Synergistic Blockade: A Powerful Therapeutic Strategy
The critical importance of this EPO-mediated communication between tumor cells and macrophages became unequivocally clear when the researchers examined the combined effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. In these experiments, mice bearing "cold" liver tumors that received only control treatment or anti-PD-1 treatment alone showed limited survival, with most succumbing within eight weeks of tumor induction. In dramatic contrast, mice with macrophages engineered to lack the EPO receptor (EPOR) exhibited significantly improved outcomes. Forty percent of these mice survived for the full 18-week duration of the experiment, even without anti-PD-1 therapy. However, when anti-PD-1 treatment was administered to mice lacking the EPOR, an astonishing result was observed: all animals survived for the entire experimental period, indicating complete tumor eradication.
"It’s simple," Dr. Engleman stated. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This demonstrates a potent synergistic effect, where targeting EPO’s immunosuppressive function unlocks the full potential of existing immunotherapies.
Future Directions and Implications for Human Cancer Therapy
The implications of this discovery for the development of novel cancer therapies are profound. Dr. Engleman and his team are actively engaged in designing therapeutic strategies that target EPO signaling in human cancers. One potential approach involves non-specifically targeting the EPO protein itself. While this could theoretically lead to anemia, a side effect that Dr. Engleman speculates might be an acceptable trade-off for a highly effective cancer treatment, it also presents challenges. A more refined strategy under consideration is the selective blockade of EPO receptors specifically on the surface of macrophages within the tumor microenvironment. This targeted approach aims to disrupt the immunosuppressive signaling without causing systemic side effects associated with broad EPO inhibition.
"I continue to be amazed by this finding," Dr. Engleman concluded. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." The research, which also involved contributions from the New York Blood Center and the pharmaceutical company ImmunEdge Inc., was supported by significant funding from the National Institutes of Health. The intellectual property surrounding this discovery is being actively pursued, with Dr. Chiu and Dr. Engleman listed as inventors on patent applications related to EPO receptor agonists and antagonists.
This research represents a significant leap forward in our understanding of cancer immunology, potentially unlocking new avenues for treating a wide range of cancers that have historically proven resistant to current therapies. By re-sensitizing "cold" tumors to the immune system, this work offers a beacon of hope for patients facing challenging diagnoses.
